Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07445022 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

Name: RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma — clinical trial record (NCT07445022)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorFudan University

Started2026-01-28

View on ClinicalTrials.gov ↗

Fudan University

624 trials monitored

See 9 trials at risk

Melanoma

1,020 trials monitored

See 45 trials at risk

This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.

Trial Details

NCT Number	NCT07445022
Lead Sponsor	Fudan University
Conditions	Melanoma Advanced
Enrollment	110 participants
Start Date	2026-01-28
Primary Completion	2028-09-30 (estimated)
Study Completion	2029-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-03